Linked Data API

Show Search Form

Search Results

1011608
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Ocrelizumab more like this
house id 1 remove filter
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of ocrelizumab as a treatment for people with primary progressive multiple sclerosis. more like this
tabling member constituency Croydon North more like this
tabling member printed
Mr Steve Reed more like this
uin 194211 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-26more like thismore than 2018-11-26
answer text <p>The Department has made no assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent an effective use of NHS resources. NICE is currently developing technology appraisal guidance on the use of ocrelizumab for treating primary progressive multiple sclerosis.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-11-26T17:46:53.237Zmore like thismore than 2018-11-26T17:46:53.237Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4268
label Biography information for Steve Reed remove filter